---

Metformin - Dosage & How to Take

Dosing

• Always take with meals - this significantly reduces GI side effects (nausea, bloating, diarrhea)
• Start low and increase gradually over several weeks - this is the key to tolerating the drug
• Swallow XR tablets whole; do not crush or chew them
• Take at roughly the same time each day

• Do not use if eGFR is below 30 mL/min (cleared by kidneys)
• Hold temporarily before CT scans or procedures using iodinated contrast dye
• Long-term use can deplete Vitamin B12 - periodic B12 testing is recommended
• Does not cause hypoglycemia on its own (no effect on insulin secretion)

---

Linagliptin (Tradjenta) - Dosage & How to Take

Dosing

• Take once daily at any time of day - with or without food
• Take at the same time each day for consistency
• Can be combined with metformin, sulfonylureas, or insulin

• If combined with a sulfonylurea (e.g., glimepiride) or insulin, your doctor may reduce the sulfonylurea/insulin dose to avoid low blood sugar
• Not for use in Type 1 diabetes or diabetic ketoacidosis
• Stop linagliptin if a GLP-1 receptor agonist (e.g., semaglutide) is started - they work on the same pathway and should not be combined
• Rarely associated with severe joint pain - report this to your doctor if it occurs

---

Taking Both Together (Metformin + Linagliptin)

• The metformin component is still taken with meals to minimize GI effects
• The linagliptin component requires no special food timing
• The combination provides complementary glucose-lowering: metformin reduces liver glucose output; linagliptin boosts insulin release after meals

---

Note: These are general dosing guidelines. Your prescribing doctor sets the specific dose for your situation, especially if you have kidney disease, liver disease, or take other medications.

---

Hematemesis 7 Days Post-Snakebite - Clinical Approach

---

Why This Is Happening - Pathophysiology

Hemostatic Defects from Snake Venom

• Procoagulant venoms (especially Russell's viper / Daboia russelli, Bothrops, Crotalids) activate Factors V and X, consuming clotting factors and causing a defibrination syndrome
• Anticoagulant/fibrinolytic venoms activate the endogenous fibrinolytic system, causing defibrinogenation
• Thrombocytopenia from direct platelet destruction or consumption
• Hemorrhagins - venom components that directly damage blood vessel walls, causing increased vascular permeability and spontaneous bleeding

Why Bleeding at 7 Days?

"Delayed onset of signs and symptoms of snake bite is rare but definitely occurs in the form of bleeding manifestations including brain haemorrhages up to one week after the bite. The possible explanation for delayed bleeding is that local blebs constitute a venom depot, which is suddenly released into the blood stream, especially when the wound is handled surgically."

• Acute Kidney Injury (AKI) from nephrotoxic venom compounds - AKI can develop up to 96 hours post-bite and persist for 1-2 weeks, aggravating bleeding tendency through uremic platelet dysfunction
• Hypopituitarism (rare, but documented complication of Russell's viper bite)
• Stress ulcer / gastric mucosal ischemia from systemic hypotension or shock during envenomation

---

Immediate Assessment

Stabilize First (ABCs)

• Airway protection (patient vomiting blood - aspiration risk)
• Two large-bore IV lines
• Cardiac monitoring, pulse oximetry
• IV fluid resuscitation if hemodynamically unstable

Urgent Labs

---

Management

1. Antivenom - First Priority

"Blood products are rarely needed; if required, they should be given only after antivenom administration."

• Give species-appropriate polyvalent antivenom if still available/indicated
• Persistent or recurrent coagulopathy with active bleeding is a clear indication for antivenom even days later
• Repeat doses may be needed if coagulopathy recurs

2. Blood Product Support (After Antivenom)

• Fresh Frozen Plasma (FFP) - for coagulation factor replacement
• Cryoprecipitate - if fibrinogen < 1 g/L (preferred for fibrinogen replacement)
• Platelet transfusion - if platelets <50,000 with active bleeding
• Packed Red Cells - for significant blood loss/anemia

3. GI Bleed Management

• Keep patient nil by mouth; nasogastric tube if needed to quantify bleeding
• Proton pump inhibitor IV (e.g., pantoprazole 80 mg bolus then infusion) - gastroprotection
• Endoscopy: once coagulopathy is corrected, consider upper GI endoscopy to identify source (variceal vs. ulcer vs. diffuse mucosal hemorrhage from VICC)
• Avoid NSAIDs and antiplatelet agents absolutely

4. Manage AKI

• Monitor urine output hourly
• Avoid nephrotoxic drugs (aminoglycosides, NSAIDs, contrast)
• Dialysis (hemodialysis or peritoneal) if oliguria persists >1-2 weeks, severe uremia, or electrolyte imbalance
• AKI may persist weeks even after coagulation normalizes

5. Monitor for Complications

• Watch for intracranial hemorrhage (altered consciousness, headache, focal neurological signs - a catastrophic but documented complication)
• Hemolysis - may worsen anemia rapidly
• Hypotension / shock - needs aggressive fluid management

---

Likely Snake Types (if in South/Southeast Asia)

---

WHO Syndrome Approach (Southeast Asia)

• Local effects + coagulopathy/bleeding = Viper bite (most likely)
• Management follows antivenom + supportive care as above

---

Key Points Summary

1. Hematemesis at day 7 = delayed/recurrent VICC - a well-recognized but serious complication
2. Give antivenom first before any blood products
3. Correct coagulopathy with FFP/cryoprecipitate/platelets after antivenom
4. IV PPI for GI mucosal protection
5. Monitor for AKI, intracranial hemorrhage, and hemolysis
6. Do not delay - active GI bleeding with coagulopathy carries high mortality if untreated

---

---

Chest X-Ray Report

---

Technical Adequacy

• Adequate inspiration (note: slightly limited view due to film being held at an angle)
• Standard PA projection
• Markers: R on patient's right (correct PA orientation)

---

Systematic Findings

• The heart is markedly enlarged
• Cardiothoracic ratio (CTR) is visually well above 0.5 (normal <0.5)
• The cardiac borders are indistinct/hazy, particularly the left heart border
• The left cardiac border appears convex and prominent - suggesting left ventricular enlargement
• The right heart border is also pushed out - suggesting right-sided or biventricular enlargement

• Bilateral perihilar haziness - "bat-wing" pattern typical of pulmonary edema (compare with the reference image above from Goldman-Cecil Medicine)
• Lower zone opacification bilaterally - consistent with alveolar edema
• The opacities are bilateral and relatively symmetrical - favoring cardiogenic cause
• No clear lobar consolidation to suggest pneumonia

• Bilateral costophrenic angle blunting - consistent with bilateral pleural effusions
• Right side appears more opacified than left at the bases

• Hilar vessels appear enlarged and indistinct (vascular congestion)
• Upper lobe vascular redistribution likely present (cephalization of flow) - a key early sign of raised pulmonary venous pressure

• Widened mediastinum due to cardiac enlargement
• Trachea appears central (no significant mediastinal shift)

• Ribs, clavicles, scapulae appear intact
• No obvious rib fractures or lytic lesions

• Both hemidiaphragms are obscured at their bases due to pleural effusions
• Right hemidiaphragm level appears elevated/obscured

• No gross subcutaneous emphysema

---

Impression

Cardiomegaly with features of congestive cardiac failure (CCF) / Acute Pulmonary Edema

1. Cardiomegaly (CTR > 0.5)
2. Bilateral pulmonary edema - perihilar "bat-wing" haziness with lower zone opacification
3. Bilateral pleural effusions - blunting of costophrenic angles

---

Differential Diagnosis

---

Recommended Next Steps

1. Urgent ECG - look for arrhythmia, LVH, ischemic changes
2. Echocardiogram - assess LV/RV function, wall motion, pericardial effusion, valvular disease
3. BNP / NT-proBNP - markedly elevated in CCF
4. ABG - assess respiratory failure severity
5. Troponin - rule out acute MI as precipitant
6. Serum electrolytes, renal function - before diuresis
7. Immediate treatment: IV furosemide, oxygen (high flow), upright positioning, consider CPAP/BiPAP if SpO₂ not improving

---

---

Pulmonary Edema Management

---

Step 1 - Identify the Hemodynamic Profile

95% of AHF patients are "wet" (congested). The patient with pulmonary edema and breathlessness is almost always "wet."

---

Step 2 - Immediate Stabilization (Phase I)

A. Positioning & Oxygen

• Sit patient upright (reduces venous return, lowers preload)
• High-flow oxygen via face mask (target SpO₂ ≥ 94%)
• Non-invasive ventilation (NIV): BiPAP or CPAP is a Class I recommendation for cardiogenic pulmonary edema
  • CPAP: 5-10 cmH₂O
  • BiPAP: IPAP 10-15 / EPAP 5 cmH₂O
  • Reduces work of breathing, improves oxygenation, reduces intubation rates
• Intubation if NIV fails, altered consciousness, or SpO₂ not maintained

B. IV Access & Monitoring

• Two large-bore IV lines
• Continuous ECG monitoring, pulse oximetry
• Urinary catheter for hourly urine output

C. Urgent Investigations

• ECG (rule out ACS, arrhythmia)
• BNP / NT-proBNP (markedly elevated confirms AHF)
• Troponin (rule out acute MI as precipitant)
• ABG
• CXR
• Echo (bedside if available - assess LV function)
• U&E, creatinine, electrolytes (before diuresis)

---

Step 3 - Drug Treatment

1. Loop Diuretics (First-line) - Class I, LOE B

• IV furosemide has a short-lived vasodilatory action (venodilation) before its diuretic effect kicks in
• Monitor urine output, electrolytes, and creatinine during therapy
• Refractory to loop diuretics? Add metolazone (thiazide) - sequential nephron blockade; or switch to continuous infusion
• Torsemide or bumetanide are alternatives if furosemide fails

2. Vasodilators (For "Wet & Warm" with adequate BP)

Do NOT give vasodilators if SBP < 90 mmHg - risk of precipitating cardiogenic shock.

3. Morphine - Use with Caution

• Historically used (venodilator, reduces anxiety/dyspnea sensation)
• Current evidence suggests worse outcomes in some registries - use judiciously if at all, in small IV doses (2-4 mg) only if extreme distress

4. Inotropes (For "Wet & Cold" - low output + congestion)

5. ACE Inhibitors / ARBs

• Not for acute pulmonary edema (may cause hypotension acutely)
• Start/continue once patient is stabilized (Phase II)

6. SGLT2 Inhibitors (Newer - Phase II onwards)

• Dapagliflozin / empagliflozin - reduce cardiac preload/afterload, improve outcomes in HFrEF and HFpEF
• Not used in acute phase but important for discharge optimization

---

Step 4 - Escalation for Refractory Cases

---

Step 5 - Treat the Precipitating Cause

---

Step 6 - Phase II (In-Hospital Optimization - ACC/AHA GDMT)

---

Monitoring Targets During Treatment

---